Altisource Portfolio Solutions S.A.·4

Mar 2, 5:11 PM ET

MASTIONI MARCELLO 4

4 · Altisource Portfolio Solutions S.A. · Filed Mar 2, 2021

Insider Transaction Report

Form 4
Period: 2021-02-26
MASTIONI MARCELLO
PRES, REAL ESTATE MARKETPLACE
Transactions
  • Exercise/Conversion

    Common Stock

    2021-02-26+3,56049,851 total
  • Tax Payment

    Common Stock

    2021-02-26$10.32/sh49$50649,802 total
  • Exercise/Conversion

    Restricted Share Units

    2021-02-262,5602,559 total
    Exercise: $0.00Common Stock (2,560 underlying)
  • Exercise/Conversion

    Restricted Share Units

    2021-02-261,0002,000 total
    Exercise: $0.00Common Stock (1,000 underlying)
Footnotes (4)
  • [F1]Of the 3,560 restricted share units ("RSUs") vesting into shares reported above, 49 shares were foregone to pay for the tax withholding with a net issuance to Mr. Mastioni of 3,558 shares. Pursuant to the terms of the award agreement, the price per share used to determine the tax withholdings was the opening price of ASPS common stock on February 26, 2021.
  • [F2]3,560 shares of ASPS common stock were received upon the vesting of previously granted RSUs pursuant to an award under the 2009 Equity Incentive Plan, as amended and the 2019 Annual Incentive Plan.
  • [F3]Represents the vesting of RSUs. The remaining 2,559 RSUs are expected to vest on June 30, 2021, pursuant to the terms of the equity award agreement, following the previously announced departure of Mr. Mastioni from the Company on May 30, 2021. Each RSU represents a contingent right to receive one share of ASPS common stock.
  • [F4]Represents the vesting of RSUs. 1,000 RSUs are expected to vest on June 30, 2021, pursuant to the terms of the equity award agreement, following the previously announced departure of Mr. Mastioni from the Company on May 30, 2021, and the remaining RSUs are to be forfeited. Each RSU represents a contingent right to receive one share of ASPS common stock.

Documents

1 file
  • 4
    f4_a1e2k00000kldqhuad-live.xmlPrimary

    PRIMARY DOCUMENT